Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001144204-19-045770 0001425738 XXXXXXXX LIVE 3 Common Stock, par value $0.0001 per share 08/04/2025 false 0001680367 82024L103 Shattuck Labs, Inc. 500 W. 5th Street Austin TX 78701 Redmile Group, LLC (415) 489-9980 Attn: Joshua Garcia One Letterman Drive Bldg D, Ste D3-300 San Francisco CA 94129 0001425738 N Redmile Group, LLC OO N DE 0.00 5652660.00 0.00 5652660.00 5652660.00 N 11.8 IA OO (1) The source of funds was working capital of certain private investment funds managed by Redmile Group, LLC (the "Redmile Funds"), including Redmile Biopharma Investments II, L.P. ("RBI II"). (2) The aggregate amount of shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that may be deemed beneficially owned by Redmile Group, LLC ("Redmile") are held directly by the Redmile Funds, including RBI II. Redmile as the investment manager to each Redmile Fund exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. (3) Percent of class calculated based on: 47,903,215 shares of Common Stock outstanding on May 14, 2025, as disclosed in the Issuer's Definitive Proxy Statement for the 2025 Annual Meeting of the Stockholders filed on Schedule 14A with the SEC on May 21, 2025 (the "Proxy Statement"). 0001650527 N Jeremy C. Green OO N X0 0.00 5652660.00 0.00 5652660.00 5652660.00 N 11.8 IN HC (1) The source of funds was working capital of the Redmile Funds, including RBI II. (2) The aggregate amount of shares of the Common Stock that may be deemed beneficially owned by Jeremy C. Green are held directly by the Redmile Funds, including RBI II. Redmile as the investment manager to each Redmile Fund exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Mr. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. (3) Percent of class calculated based on: 47,903,215 shares of Common Stock outstanding on May 14, 2025, as disclosed in the Proxy Statement. 0001772230 N Redmile Biopharma Investments II, L.P. WC N DE 0.00 3338997.00 0.00 3338997.00 3338997.00 N 7.0 PN (1) Percent of class calculated based on: 47,903,215 shares of Common Stock outstanding on May 14, 2025, as disclosed in the Proxy Statement. Common Stock, par value $0.0001 per share Shattuck Labs, Inc. 500 W. 5th Street Austin TX 78701 This amendment No. 3 to Schedule 13D amends and supplements the Schedule 13D filed with the SEC on October 15, 2020, amendment No. 1 to the Schedule 13D filed with the SEC on December 21, 2023, and amendment No. 2 to the Schedule 13D filed with the SEC on December 6, 2024 (collectively, the "Prior Schedule 13D") by Redmile Group, LLC ("Redmile"), Jeremy C. Green, and Redmile Biopharma Investments II, L.P. ("RBI II") relating to the Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 3 shall have the meanings set forth in the Prior Schedule 13D. Except as specifically amended by this Amendment No. 3, the Prior Schedule 13D is unchanged. The information in Item 6 below is incorporated herein by reference. Item 5 of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: (a) The aggregate amount of shares of Common Stock that may be deemed beneficially owned by the Reporting Persons is comprised of the following: (i) 456,784 shares of Common Stock held by Redmile Capital Fund, L.P., (ii) 494,932 shares of Common Stock held by Redmile Capital Offshore Master Fund, Ltd., (iii) 374,149 shares of Common Stock held by Redmile Capital Offshore II Master Fund, Ltd., (iv) 301,022 shares of Common Stock held by Redmile Strategic Long Only Trading Sub, Ltd., (v) 467,910 shares of Common Stock held by Redmile Strategic Trading Sub, Ltd., (vi) 3,338,997 shares of Common Stock held by RBI II, and (vii) 105,930 shares of Common Stock held by RedCo I, L.P. Redmile is the investment manager to each of the private investment funds listed in items (i) through (vii) (the "Redmile Funds") and, in such capacity, exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such shares, if any. Subject to the Beneficial Ownership Blocker (as defined below), Redmile and Mr. Green may also be deemed to beneficially own 3,100,823 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. Pursuant to the terms of the Pre-Funded Warrants, the Common Stock that may be acquired upon exercise of the Pre-Funded Warrants shall be limited to the extent that, following such exercise, the total number of shares of Common Stock then beneficially owned by the holder of the Pre-Funded Warrants, together with such holder's affiliates and any other person whose beneficial ownership of Common Stock would be aggregated with such holder's for the purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), would exceed the Beneficial Ownership Limitation (the "Beneficial Ownership Blocker"). The "Beneficial Ownership Limitation" is 9.99% of the shares of Common Stock then issued and outstanding, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. Because the percentage of shares of Common Stock held directly by the Redmile Funds at the time of this filing exceeds 9.99% in the aggregate, the exercise of the Pre-Funded Warrants held by Redmile Funds are limited in their entirety by the Beneficial Ownership Blocker and the Reporting Persons therefore cannot be deemed to have beneficial ownership of any of the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and such shares have not been included in the aggregate amount of securities reported in this Schedule 13D. Redmile and Mr. Green may also be deemed to beneficially own 112,936 shares of Common Stock subject to options to purchase shares of Common Stock that are exercisable within 60 days of the date of this filing. The stock options were granted to Mike Lee, a managing director of Redmile, in connection with his service as a member of the Board of Directors. Pursuant to the policies of Redmile, Mr. Lee holds the stock options as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock options to Redmile. For purposes of this Schedule 13D, the percent of class is calculated based on 47,903,215 shares of Common Stock outstanding on May 14, 2025, as disclosed in the Proxy Statement. Redmile Group, LLC: (1) Sole Voting Power: 0 (2) Shared Voting Power: 5,652,660 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 5,652,660 Jeremy C. Green: (1) Sole Voting Power: 0 (2) Shared Voting Power: 5,652,660 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 5,652,660 Redmile Biopharma Investments II, L.P.: (1) Sole Voting Power: 0 (2) Shared Voting Power: 3,338,997 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 3,338,997 Item 6 of the Prior Schedule 13D is hereby amended and supplemented by replacing the last paragraph of Item 6 with the following paragraphs: Securities Purchase Agreement On August 4, 2025, the Issuer entered into a securities purchase agreement with certain institutional accredited investors (the "Purchase Agreement"), including RBI II and certain other Redmile Funds. Pursuant to the terms of the Purchase Agreement, the Issuer will issue and sell to RBI II and certain other Redmile Funds in a private placement Pre-Funded Warrants to purchase up to an aggregate of 4,097,730 shares of Common Stock, each with an exercise price of $0.0001 per Pre-Funded Warrant, and accompanying warrants (the "Common Warrants") to purchase up to an aggregate of 4,097,730 shares of Common Stock, each with an exercise price of $1.0846 per Common Warrant, at a combined price of $0.8676, upon the closing of the transaction. Of the warrants to be issued and sold to the Redmile Funds in the private placement, RBI II will purchase Pre-Funded Warrants to purchase up to an aggregate of 2,048,423 shares of Common Stock and Common Warrants to purchase up to an aggregate of 2,048,423 shares of Common Stock upon the closing of the transaction. The closing of the private placement is subject to the satisfaction or waiver of certain material conditions specified in the Purchase Agreement, including the regulatory clearance of the Issuer's investigational new drug application by the U.S. Food and Drug Administration prior to the closing. The foregoing summary of the Purchase Agreement is not intended to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is filed as Exhibit 99.7 to this Schedule 13D and is incorporated herein by reference. Side Letter Agreement In connection with the execution of the Purchase Agreement, Redmile also entered into a side letter agreement with the Issuer, dated as of August 4, 2025 (the "Side Letter"). Pursuant to the terms of the Side Letter, upon the closing of the private placement, Redmile will have (a) the right to participate in future equity offerings of the Issuer up to its pro rata ownership percentage in the Issuer, and (b) the right to designate a non-voting observer to the Issuer's Board of Directors subject to Redmile maintaining a certain beneficial ownership interest in the Issuer's Common Stock. The foregoing summary of the Side Letter is not intended to be complete and is qualified in its entirety by reference to the full text of the Side Letter, which is filed as Exhibit 99.8 to this Schedule 13D and is incorporated herein by reference. Except as described above, no contracts, arrangements, understandings, or relationships (legal or otherwise) exist between any Reporting Person and any person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies. Except as described above, none of the Reporting Persons is a party to any arrangement whereby securities of the Issuer are pledged or are otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities. Exhibit 99.7 Securities Purchase Agreement, dated August 4, 2025, by and among the Issuer and each purchaser listed on the signature page thereto (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed on August 5, 2025). Exhibit 99.8 Side Letter Agreement, dated August 4, 2025, by and between Redmile and the Issuer. Redmile Group, LLC /s/ Jeremy C. Green Managing Member 08/06/2025 Jeremy C. Green /s/ Jeremy C. Green Jeremy C. Green 08/06/2025 Redmile Biopharma Investments II, L.P. /s/ Jeremy C. Green Managing Member of Redmile Group, LLC, the Managing Member of Redmile Biopharma Investments II (GP), LLC, its General Partner 08/06/2025